ArticleInternational journal of clinical oncology2016
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
Article in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Role of Aldo-Keto reductase family 1 member C in cancer progression: a special focus on the role of AKR1C1 in pancreatic cancer.Medical oncology (Northwood, London, England) · 2025Article
- Cancer to Cataracts: The Mechanistic Impact of Aldo-Keto Reductases in Chronic Diseases.The Yale journal of biology and medicine · 2024Review
- Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types.Nature communications · 2024Article
- SRSF3-Mediated Ki67 Exon 7-Inclusion Promotes Head and Neck Squamous Cell Carcinoma Progression via Repressing AKR1C2.International journal of molecular sciences · 2023Article
- Article
- AKR1C1 Contributes to Cervical Cancer Progression via Regulating TWIST1 Expression.Biochemical genetics · 2021Article
- Genome-scale meta-analysis of breast cancer datasets identifies promising targets for drug development.Journal of biological research (Thessalonike, Greece) · 2021Article
- Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling.Frontiers in oncology · 2021Article
- Screening and Identification of Key Common and Specific Genes and Their Prognostic Roles in Different Molecular Subtypes of Breast Cancer.Frontiers in molecular biosciences · 2021Article
- Evaluation of Ferroptosis-related GeneInternational journal of general medicine · 2021Article
- Identifying a Ferroptosis-Related Gene Signature for Predicting Biochemical Recurrence of Prostate Cancer.Frontiers in cell and developmental biology · 2021Article
- AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K/AKT signaling pathway.Journal of cellular and molecular medicine · 2020Article
- Increased Efficacy of Histone Methyltransferase G9a Inhibitors AgainstFrontiers in oncology · 2020Article
- AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies.Oncology letters · 2019Article
- Secretome analysis of oral keratinocytes chronically exposed to shisha.Cancer biomarkers : section A of Disease markers · 2019Article
- Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma.Journal of Cancer · 2019Article
- Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma.Oncology letters · 2018Article
- Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy.Frontiers in pharmacology · 2017Review
- An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.Journal of translational medicine · 2016Article
- Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone.Chronic stress (Thousand Oaks, Calif.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStromal fibroblasts influence tumor growth and progression. We evaluated two aldo-keto reductases, AKR1C1 and AKR1C2, in stromal fibroblasts and carcinoma cells as prognostic factors in primary human breast cancer. They are involved in intratumoral progesterone metabolism.
methodsImmunohistochemistry was performed on tissue microarrays from 504 core biopsies from breast cancer patients. Primary endpoints were disease-free (DFS) and overall (OS) survival.
resultsAKR1C1 and AKR1C2 expression in fibroblasts and tumor cells correlated with favorable tumor characteristics, such as small tumor size and negative nodal status. In univariate analysis, AKR1C1 expression in carcinoma cells correlated positively with DFS und OS; AKR1C2 expression in both fibroblasts and tumor cells also showed a positive correlation with DFS and OS. In multivariate analysis, AKR1C1 expression in carcinoma cells was an independent prognostic marker.
conclusionIt can be assumed that our observations are due to the independent regulatory function of AKR1C1/2 in progesterone metabolism and therefore provide a basis for new hormone-based therapy options for breast cancer patients, independent of classic hormone receptor status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.